## Core Concept
The question tests the understanding of the pharmacological management of bone disorders, specifically the role of RANKL (Receptor Activator of NF-κB Ligand) in bone resorption. RANKL is a protein crucial for the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption.

## Why the Correct Answer is Right
The correct answer, **Denosumab**, is a monoclonal antibody that binds to RANKL with high affinity, thereby inhibiting its interaction with RANK on osteoclasts. This inhibition significantly reduces bone resorption by decreasing the formation, activation, and survival of osteoclasts. Denosumab is used in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because it does not correspond to a known drug that works by binding RANKL.
- **Option B:** This option is incorrect as it does not represent a drug that inhibits bone resorption through the RANKL pathway.
- **Option C:** This option is incorrect because it is not associated with the mechanism of action described.
- **Option D:** This option is incorrect because, although some bisphosphonates do reduce bone resorption, they do not work by binding RANKL; instead, they inhibit osteoclast-mediated bone resorption by a different mechanism.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **Denosumab** is a significant drug in the management of bone diseases characterized by increased bone resorption. It is administered subcutaneously and has a significant impact on reducing the risk of vertebral, non-vertebral, and hip fractures in patients with osteoporosis.

## Correct Answer Line
**Correct Answer: D. Denosumab**